Cefuroxime in the Treatment of Bacterial Infections in Seriously Ill Patients Admitted to an Intensive Care Unit

Gobernado, M; Gudin, Jeffrey; Santos, M.C.P.; Gregori, J.; Cantón, Emilia; Ferrando, C.

doi:10.1177/00359157770700s917

Cited by 4 publications

(1 citation statement)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3O Reports of changes in hematologic parameters have been sporadic. There have been occasional reports of decreased hemoglobin6*Ie2 or positive Coomb's tests.37 Gold did not notice such changes in any Of her 77 patients.% Eosinophilia (2 500 mm3) has been reported by [67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82] Gold observed eosinophilia in 14% of those children treated for 5 days or less and in 32% of those treated for longer Also obselved in Gold's series was neutro-Penis (< 1 500/mm3 in 18% of 28 children treated for more than 5 days with cefur~xime.~~ The clinical significance of these hemtologic changes is not ap-Parent. Follow-up studies have shown normalization Of hematologic parameters once therapy is discontinued.…”

Section: Side Effects and Toxicitymentioning

confidence: 89%

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

Gold

Rodríguez

1983

Pharmacotherapy

View full text Add to dashboard Cite

Cefuroxime is a second generation cephalosporin with a broad antimicrobial activity against both Gram-positive and Gram-negative organisms. It has excellent in vitro activity against staphylococcal strains, streptococcal strains (other than enterococci), N. gonorrhoaae, H. infhenzae and N. meningitidis. It also has excellent in vitro activity against members of the Enterobacteriaceae with the exception of Serratia and indole-posltive Proteus. Ps. aeruginosa and 8. tragilis are resistant. Cefuroxime is relatively free of serious side effects. It is metabolically stable, and most of it is excreted unchanged in the urine.

show abstract

Section: Side Effects and Toxicitymentioning

confidence: 89%

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

Gold

Rodríguez

1983

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

Gold

Rodríguez

1983

Pharmacotherapy

View full text Add to dashboard Cite

Cefuroxime is a second generation cephalosporin with a broad antimicrobial activity against both Gram‐positive and Gram‐negative organisms. It has excellent in vitro activity against staphylococcal strains, streptococcal strains (other than enterococci), N. gonorrhoeae, H. influenzae and N. meningitidis. It also has excellent in vitro activity against members of the Enterobacteriaceae with the exception of Serratia and indole‐positive Proteus. Ps. aeruginosa and B. fragilis are resistant. Cefuroxime is relatively free of serious side effects. It is metabolically stable, and most of it is excreted unchanged in the urine. Three fourths of it are distributed in the extravascular compartment. Blood levels exceed the in vitro minimum inhibitory concentrations for many important gram negative pathogens. Clinical studies have shown cefuroxime to be effective therapy for infections of soft tissue, respiratory tract, urinary tract, genital tract (caused by N. gonnorrhoeae) and the central nervous system. Superinfections with Ps. aeruginosa and enterococcal strains may present a problem. In spite of excellent diffusion into bone and joint tissues, the available clinical data are too limited to make a recommendation for its use in bone and joint infections.

show abstract

A survey of the sensitivity of fresh clinical isolates to cefuroxime and other antibiotics.

Potaschmacher¹,

Dash²,

Jefferson³

et al. 1979

J Clin Pathol

View full text Add to dashboard Cite

SUMMARY The sensitivities to cefuroxime and cephradine of potentially pathogenic bacteria isolated in two British general hospitals comprising 900 beds have been assessed. In a three-month period, 2537 strains were studied; 30 tkg cefuroxime discs were used with 2511 strains, and cephradine discs of the same strength were used with 2525 strains. The organisms were also examined routinely for sensitivity to other antibiotics. Overall, 91[7 % of the isolates were sensitive to cefuroxime and 85-8 % were inhibited by cephradine, the differences in percentage strain susceptibility to cefuroxime and cephradine being mainly a result of the greater activity of cefuroxime against the Gram-negative bacteria. The wide antibacterial effectiveness of cefuroxime should make it a useful antibiotic for the treatment of serious infections including those conditions in which the causative organism has not been identified.

show abstract

Cefuroxime in the Treatment of Bacterial Infections in Seriously Ill Patients Admitted to an Intensive Care Unit

Cited by 4 publications

References 10 publications

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

Cefuroxime: Mechanisms of Action, Antimicrobial Activity, Pharmacokinetics, Clinical Applications, Adverse Reactions and Therapeutic Indications

A survey of the sensitivity of fresh clinical isolates to cefuroxime and other antibiotics.

Contact Info

Product

Resources

About